Neurocrine BiosciencesNBIX
Recorded

Neurocrine Biosciences Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration28 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Akash TewariHead of Pharma and Biotech Research

Good morning, everyone. Really appreciate you joining us. My name is Akash Tewari. I head our pharma and biotech research efforts internally within Jefferies. I have the pleasure of hosting the Neurocrine management team. Very, very big 2027 catalyst slate for the company. You would argue maybe the most important in the company's history. A lot to talk about the pipeline, and also really the commercial portfolio as well. Very much looking forward to it. Kyle, why don't I hand it off to you for some intro remarks, and we will get started.

Kyle GanoCEO

That would be great. Thanks, Akash, and thanks to Jefferies for the invitation. Really is great to be here. Maybe just to start things off here, I would like to also thank Jefferies for the following benefit of flying out here. For 10 hours, there was no Wi-Fi on our flight. I think those who know the benefit of that. No email, no MS Teams, no text messages from the family. It did give me a good opportunity to think, and I was thinking a lot about how much has changed at Neurocrine over the past couple years. When I stepped into the CEO role, we were a single-product company. That was just Ingrezza. Of course, we had a lot of ambition, and that ambition continues to this day. But fast-forward to Q3, we have got three first-in-class medicines and expanding portfolio.

Kyle GanoCEO

If you look at just our Q3 performance, we are annualizing now at about $4.5 billion in sales. I learned a lot along the way over the past couple years as well. Diversification is a wonderful thing when you are talking about the commercial portfolio or the R&D pipeline, and I know we will get some questions, some Q&A on that. I have also learned that when you have three medicines versus one, you have a lot more to worry about. My family tells me that I perfected that part of the job over the past couple years. But all jokes aside, it has really been a pleasure working in this role and capacity at Neurocrine. I am pleased at the progress we have made over the past couple years, starting with Ingrezza in Q3, $800 million in sales. We had about 15% year-to-year growth, double-digit volume growth, record TRX, record NRX.

Kyle GanoCEO

We raised our guidance for the second time. I can go on and on. But it really does speak to the strength of the brand and our team and the hard work that we put into Ingrezza over the past couple years. CRENNESITY, our second year into the launch. We have not completed the full second year, but we are annualizing at a rate now about $850 million in sales. Of the 20,000 patients that are out there in congenital adrenal hyperplasia, we have about 15%, a little bit more than 15% under care of CRENNESITY. You really can see a line of sight for us changing the standard of care. Then with VYKAT XR, we have added another important medicine to our portfolio that we think has the potential to be a really long-term, best-in-class medicine for patients with Prader-Willi syndrome. So we are looking to make good progress there in 2027.

Kyle GanoCEO

But what's even more exciting to see is that we're not just growing. The business is becoming stronger. We are becoming a much more diversified one. Approximately 30% of our revenue comes from medicines other than INGREZZA. That would have been unheard of to think about just a few years ago. Then comes 2027. We have multiple phase II and phase III data readouts across our pipeline. osavampator in MDD will read out phase III studies. direclidine in schizophrenia will also read out phase III studies. These are potential medicines that are trajectory-changing for a company like Neurocrine. I think related to that, this year we have six new phase I starts, five new phase II starts. We've never been this productive from an R&D perspective in all of our history. So I think it paints a picture of a company that's evolving.

Kyle GanoCEO

We're going to be having meaningful clinical data readouts as time moves along. That will be the norm, not the exception. So when I look back at all the progress that we've made, you really see a company that has a strong commercial foundation, has all the financial resources, and a really rich and diverse pipeline that will drive growth well into the future. So that literally is a flyby of the pipeline that came from sitting on the plane for 10 hours. I'm sure we can dive into some of the details now, but appreciate the opportunity.

Matt AbernethyCFO

Hey, Kyle, before you do that, I have two value-added comments.

Matt AbernethyCFO

Sure. First, we are making forward-looking statements, so check out our SEC filings.

Matt AbernethyCFO

There you go. The second, I guess, value add is your team doesn't know that you're stressed, so that's a good thing.

Kyle GanoCEO

That's very good. There you go.

Akash TewariHead of Pharma and Biotech Research

There we go. For the record, I never do work on flights. I am just sitting here watching rom-coms. Anyway, let us get started. I think over the last two years with INGREZZA, there have been moving parts, right? There is a, "Oh, wow, maybe we kind of underinvested in certain areas," and there has been the big push with Teva. There has been the IRA. There has been the advent, if you can call it that, of AUSTEDO XR and what that has done from a pricing perspective. So there have been moving parts with the VMAT2 class, but it definitely, since talking to, looking at Teva and their comments, but then also looking at your team, the error bars in terms of the commercial outlook for both products seems to have narrowed, and there seems to be increased visibility that maybe was not there in the last couple years.

Akash TewariHead of Pharma and Biotech Research

Do those comments kind of resonate with you? I know you talked about 2027 pricing impact for INGREZZA on the Q3 call, but what is underlying that also seems to be a really healthy confidence on volume uptick. So do we feel like we have rebased in terms of the commercial trajectory? Let us know as we go out to the end of the decade, what is the CAGR of this product as it reaches maturity?

Kyle GanoCEO

Well, maybe I will start, and then Matt, if you have some comments and thoughts there. I think you touched on a couple different things there, and maybe I will just share my general perspective on INGREZZA and the TD market. It is amazing to think that nine years in, we are still talking about a whole category that is growing in the mid-teens, and that is exactly what we have here. I think the underlying demand stems from the fact that TD itself, tardive dyskinesia, is a function of antipsychotic prescription volume and growth. That is the source and cause of TD, and that continues to grow at a clip of about 3% per year. There were 75 million prescriptions written last year, and that is a multiple of the growth rate of the general population.

Kyle GanoCEO

So that is why you have seen us over the years have to update our prevalence numbers, because the denominator, the patient number, actually is increasing over time. So we have always felt like we have been trying to play catch-up here in the patients that are out there, diagnosing them, and then getting them under the care of INGREZZA. It has led us to have a couple sales force expansions, so those are some of the things that we have learned over the years. For the foreseeable future, antipsychotics are not going away. We think we have got maybe a different type of approach to treat patients that have diseases of psychosis with our muscarinics, but those are a few years out. Antipsychotics will continue to be a driving force for patients with these really debilitating diseases and conditions. So we have this underlying market that continues to grow.

Kyle GanoCEO

Ingrezza fills that need there, and we think we've got a medicine that wins on clinical performance, ease of use, and even on price. That's what's been winning the day in terms of payers and healthcare providers over time. Now, what I would say about the dynamics of the marketplace itself is that for the longest time, it's been a two-product category where companies contract with plans, as we've seen in other disease states and conditions. Next year, we move into a new era, if you will, where the two brands are working in different places when it comes to that area. We have our competitor in this space, Teva, that is going to be entering their first year of the IRA using their maximum fair price that will be pulled in overall, and they'll have great access.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day